IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
Did someone say severe #PAD? We’ll be right over! #DISRUPTPAD3, the largest-ever randomized clinical trial of sever… https://t.co/HAZsW88daB
The swell is building… A new wave of peripheral calcium data is coming! Mark your calendars for the unveiling of… https://t.co/Mdji7Z79F2
Beautiful #ShockwaveS4 case, Dr. @DrCardiV! Very successful treatment of #CLI and CTO of the peroneal & PT. Thank y… https://t.co/DlQY9N479G
Get to know #ShockwaveS4! Specifically designed to crack challenging #BTK calcium & minimize vessel recoil, this… https://t.co/bJmCjm0kQU
November 7. #VIVA20. A New Wave of Calcium Data is Coming.
Learn more about #DISRUPTPAD3, the largest-ever randomi… https://t.co/PAv944mKwn
Want to learn more about managing severe calcium in tibial vessels with #Atherectomy & #IntravascularLithotripsy? D… https://t.co/OD6x4bhiKT
The long-awaited pivotal coronary #ShockwaveIVL data is out. Read the #DISRUPTCAD3 results in the @JACCJournals pub… https://t.co/XXqDsBSmDn
@imagine654 Hi @imagine654, thanks for asking. The TCT Late-Breaking presentation is at 12:30 PM ET, when the data… https://t.co/hdhLhHaBhG
It’s finally happening... #DISRUPTCAD3 is today! Tune in for the unveiling of the pivotal coronary #ShockwaveIVL da… https://t.co/xczMjreiRd
The biggest coronary #ShockwaveIVL study to date – 384 patients from 47 global sites – is being unveiled in the Lat… https://t.co/nR7sNPz8kS
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
